Hematologic Malignancy
Acute Myeloid Leukemia
CI-CAN-00001674AML · ANLLExplore in graph →
Hematologic789 active trials18 approved drugs279 evidence items
Loading cancer entity…
Loading cancer entity…
Hematologic Malignancy
CI-CAN-00001674AML · ANLLExplore in graph →
Clinical trials
2,964 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (536)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01823198 | Donor Natural Killer Cells and Donor Stem Cell Transplant in Treating Patients With High Risk Myeloid Malignancies | completed | Phase 1 / Phase 2 | 63 | M.D. Anderson Cancer CenterOTHER | 1 | Nov 7, 2023 | clinicaltrials |
| NCT02639559 | Safety and Efficacy of BL-8040 for the Mobilization of Donor Hematopoietic Stem Cells and Allogeneic Transplantation in Patients With Advanced Hematological Malignancies | completed | Phase 2 | 50 | Washington University School of MedicineOTHER | 1 | Nov 7, 2023 |
| clinicaltrials |
| NCT03613727 | Therapeutic Use of Intravenous Vitamin C in Allogeneic Stem Cell Transplant Recipients | completed | Phase 2 | 61 | Virginia Commonwealth UniversityOTHER | 1 | Nov 7, 2023 | clinicaltrials |
| NCT03671564 | Study of Milademetan in Japanese Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) | completed | Phase 1 | 14 | Daiichi Sankyo Co., Ltd.INDUSTRY | 1 | Nov 7, 2023 | clinicaltrials |
| NCT04055844 | Multi-Ctr PII Cmb.Modality Tx Ruxolitinib, Decitabine, and DLI for Post HSCT in AML/MDS | completed | Phase 2 | 14 | Masonic Cancer Center, University of MinnesotaOTHER | 1 | Nov 7, 2023 | clinicaltrials |
| NCT02989844 | Relapse Prophylaxis With N-803 for AML and MDS Pts Following Allo HSCT | completed | Phase 2 | 20 | Masonic Cancer Center, University of MinnesotaOTHER | 1 | Nov 3, 2023 | clinicaltrials |
| NCT03728699 | Microbiota Changes in Acute Myeloid Leukemia Patients Undergoing Intensive Chemotherapy | completed | — | 54 | Masonic Cancer Center, University of MinnesotaOTHER | 1 | Nov 3, 2023 | clinicaltrials |
| NCT02117297 | SCT Plus Immune Therapy in Average Risk AML/MDS | completed | Phase 2 | 26 | New York Medical CollegeOTHER | 1 | Oct 26, 2023 | clinicaltrials |
| NCT02221310 | Immunochemotherapy and AlloSCT in Patients With High Risk CD33+ AML/MDS | completed | Phase 2 | 25 | New York Medical CollegeOTHER | 1 | Oct 26, 2023 | clinicaltrials |
| NCT00571662 | Safety and Efficacy of Pentostatin and Low Dose TBI With Allogenic Peripheral Blood Stem Cell Transplant | completed | Phase 2 | 76 | University of NebraskaOTHER | 1 | Oct 24, 2023 | clinicaltrials |
| NCT03701295 | Pinometostat and Azacitidine in Treating Patients With Relapsed, Refractory, or Newly Diagnosed Acute Myeloid Leukemia With 11q23 Rearrangement | completed | Phase 1 / Phase 2 | 1 | National Cancer Institute (NCI)NIH | 1 | Oct 18, 2023 | clinicaltrials |
| NCT05048498 | Pharmacokinetics, Tolerability and Safety of NEX-18a | completed | Phase 1 | 2 | Nanexa ABINDUSTRY | 1 | Oct 17, 2023 | clinicaltrials |
| NCT04075747 | A Phase 1b Master Trial to Investigate CPX-351 in Subjects With Previously Untreated Acute Myeloid Leukemia(V-FAST) | completed | Phase 1 | 57 | Jazz PharmaceuticalsINDUSTRY | 1 | Oct 16, 2023 | clinicaltrials |
| NCT03096782 | Umbilical Cord Blood Transplant With Added Sugar and Chemotherapy and Radiation Therapy in Treating Patients With Leukemia or Lymphoma | completed | Phase 2 | 6 | M.D. Anderson Cancer CenterOTHER | 1 | Oct 11, 2023 | clinicaltrials |
| NCT02649764 | Prexasertib (LY2606368), Cytarabine, and Fludarabine in Patients With Relapsed or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome | completed | Phase 1 | 15 | M.D. Anderson Cancer CenterOTHER | 1 | Oct 4, 2023 | clinicaltrials |
| NCT01056523 | Use of Ribavirin and Low Dose Ara-C to Treat Acute Myeloid Leukemia | completed | Phase 1 / Phase 2 | 29 | Jewish General HospitalOTHER | 1 | Oct 2, 2023 | clinicaltrials |
| NCT02073838 | Ribavirin and Hedgehog Inhibitor With or Without Decitabine in AML | completed | Phase 2 | 23 | Sarit AssoulineOTHER | 1 | Sep 29, 2023 | clinicaltrials |
| NCT02767388 | Electrophysiological Biomarkers of Chemotherapy-related Cognitive Impairment and Recovery(Chemobrain) | completed | — | 45 | University of NebraskaOTHER | 1 | Sep 29, 2023 | clinicaltrials |
| NCT02771197 | Lymphodepletion and Anti-PD-1 Blockade to Reduce Relapse in AML Patient Not Eligible for Transplant | completed | Phase 2 | 20 | Northside Hospital, Inc.OTHER | 1 | Sep 28, 2023 | clinicaltrials |
| NCT00003838 | Specialized Blood Cell Transplants for Cancers of the Blood and Bone Marrow | completed | Phase 2 | 202 | National Heart, Lung, and Blood Institute (NHLBI)NIH | 1 | Sep 21, 2023 | clinicaltrials |
| NCT02122081 | Organ-Sparing Marrow-Targeted Irradiation Before Stem Cell Transplant in Treating Patients With High-Risk Hematologic Malignancies | completed | Phase 1 | 33 | Sumithira VasuOTHER | 1 | Sep 21, 2023 | clinicaltrials |
| NCT02661035 | Allo HSCT Using RIC for Hematological Diseases | completed | Phase 2 | 156 | Masonic Cancer Center, University of MinnesotaOTHER | 1 | Sep 21, 2023 | clinicaltrials |
| NCT00106600 | Pixantrone (BBR 2778) in Patients With Refractory Acute Myelogenous Leukemia (AML) | completed | Phase 1 / Phase 2 | 12 | CTI BioPharmaINDUSTRY | 1 | Sep 18, 2023 | clinicaltrials |
| NCT04774744 | Effect of Digital Health Coaching Program on Self-efficacy and Patient Reported Outcomes of Patients With Newly Diagnosed Acute Myeloid Leukemia or Chronic Lymphocytic Leukemia | completed | N/A | 157 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 18, 2023 | clinicaltrials |
| NCT01696461 | A Phase II Study Evaluating the Safety and Efficacy of Subcutaneous Plerixafor | completed | Phase 2 | 127 | Center for International Blood and Marrow Transplant ResearchNETWORK | 1 | Sep 14, 2023 | clinicaltrials |
| NCT01951885 | Tac, Mini-MTX, MMF Versus Tac, MTX for GVHD Prevention | completed | Phase 3 | 101 | Case Comprehensive Cancer CenterOTHER | 1 | Sep 11, 2023 | clinicaltrials |
| NCT02642965 | Liposome-encapsulated Daunorubicin-Cytarabine, Fludarabine Phosphate, Cytarabine, and Filgrastim in Treating Younger Patients With Relapsed or Refractory Acute Myeloid Leukemia | completed | Phase 1 / Phase 2 | 38 | Children's Oncology GroupNETWORK | 2 | Sep 8, 2023 | clinicaltrials |
| NCT02873338 | Dociparstat Sodium (CX-01) Combined With Standard Induction Therapy for Newly Diagnosed Acute Myeloid Leukemia | completed | Phase 2 | 75 | Jazz PharmaceuticalsINDUSTRY | 1 | Sep 7, 2023 | clinicaltrials |
| NCT03390296 | OX40, Venetoclax, Avelumab, Glasdegib, Gemtuzumab Ozogamicin, and Azacitidine in Relapsed or Refractory Acute Myeloid Leukemia | completed | Phase 1 / Phase 2 | 50 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 5, 2023 | clinicaltrials |
| NCT03537560 | Detection of IDH2 Mutations and Monitoring Molecular Residual Disease in Patients With AML | completed | — | 334 | Chang Gung Memorial HospitalOTHER | 1 | Aug 31, 2023 | clinicaltrials |
| NCT04402541 | Study of CB-5339 in Acute Myeloid Leukemia or Myelodysplastic Syndrome | completed | Phase 1 | 55 | Cleave Therapeutics, Inc.INDUSTRY | 2 | Aug 31, 2023 | clinicaltrials |
| NCT03531918 | Gemtuzumab Ozogamicin With G-CSF, Cladribine, Cytarabine & Mitoxantrone for Untreated AML & High-Grade Myeloid Neoplasm | completed | Phase 1 / Phase 2 | 66 | Fred Hutchinson Cancer CenterOTHER | 1 | Aug 30, 2023 | clinicaltrials |
| NCT04443751 | A Safety and Efficacy Study of SHR-1702 Monotherapy in Patients With Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS) | completed | Phase 1 | 31 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Aug 24, 2023 | clinicaltrials |
| NCT03512197 | A Global Study of the Efficacy and Safety of Midostaurin + Chemotherapy in Newly Diagnosed Patients With FLT3 Mutation Negative (FLT3-MN) Acute Myeloid Leukemia (AML) | completed | Phase 3 | 511 | Novartis PharmaceuticalsINDUSTRY | 20 | Aug 21, 2023 | clinicaltrials |
| NCT04712942 | Treatment of MDS/AML Patients With an Impending Hematological Relapse With AZA or ATA and Pevonedistat | completed | Phase 2 | 14 | University of LeipzigOTHER | 1 | Aug 21, 2023 | clinicaltrials |
| NCT02936089 | Risk Stratification-directed Therapy for AML With t(8;21) /AML1-ETO+ | completed | N/A | 207 | Nanfang Hospital, Southern Medical UniversityOTHER | 0 | Aug 8, 2023 | clinicaltrials |
| NCT03267186 | Ibrutinib in Preventing Acute Leukemia in Patients After Reduced-Intensity Conditioning and Stem Cell Transplant | completed | Phase 2 | 8 | Andrew RezvaniOTHER | 1 | Aug 1, 2023 | clinicaltrials |
| NCT03435848 | Efficacy and Safety of BST-236 in Newly Diagnosed Acute Myeloid Leukemia Patients, Unfit for Standard Induction Therapy(ELPIS) | completed | Phase 2 | 66 | BioSight Ltd.INDUSTRY | 2 | Jul 27, 2023 | clinicaltrials |
| NCT02575963 | Lintuzumab-Ac225 in Older Acute Myeloid Leukemia (AML) Patients | completed | Phase 1 / Phase 2 | 40 | Actinium PharmaceuticalsINDUSTRY | 2 | Jul 20, 2023 | clinicaltrials |
| NCT02847130 | Identifying, Understanding, and Overcoming Barriers to the Use of Clinical Practice Guidelines in Pediatric Oncology | completed | — | 530 | Children's Oncology GroupNETWORK | 2 | Jul 19, 2023 | clinicaltrials |
| NCT03050216 | QUILT-3.033: Haplo NK With SQ ALT-803 for Adults With Relapsed or Refractory AML | completed | Phase 2 | 8 | Masonic Cancer Center, University of MinnesotaOTHER | 1 | Jul 18, 2023 | clinicaltrials |
| NCT02842827 | A Study of Bomedemstat (IMG-7289/MK-3543) With and Without ATRA, in Participants With Advanced Myeloid Malignancies (IMG-7289-CTP-101/MK-3543-001) | completed | Phase 1 / Phase 2 | 45 | Imago BioSciences, Inc., a subsidiary of Merck & Co., Inc., (Rahway, New Jersey USA)INDUSTRY | 1 | Jul 11, 2023 | clinicaltrials |
| NCT02728050 | Filgrastim, Cladribine, Cytarabine, and Mitoxantrone With Sorafenib in Treating Patients With Newly-Diagnosed, Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome | completed | Phase 1 / Phase 2 | 84 | University of WashingtonOTHER | 1 | Jul 5, 2023 | clinicaltrials |
| NCT01572662 | Allogeneic Transplantation Using Timed Sequential Busulfan and Fludarabine Conditioning | completed | Phase 2 | 201 | M.D. Anderson Cancer CenterOTHER | 1 | Jun 29, 2023 | clinicaltrials |
| NCT04562792 | Low Dose Daunorubicin in Pediatric Relapsed/Refractory Acute Leukemia | completed | Phase 2 | 1 | Children's Mercy Hospital Kansas CityOTHER | 1 | Jun 28, 2023 | clinicaltrials |
| NCT03719534 | Haplo HCT vs Haplo-cord HCT for Patients With AML | completed | Phase 3 | 134 | The First Affiliated Hospital of Soochow UniversityOTHER | 1 | Jun 27, 2023 | clinicaltrials |
| NCT02141828 | A Phase 1 Dose Escalation and Expanded Cohort Study of EPZ-5676 in the Treatment of Pediatric Patients With Relapsed/Refractory Leukemias Bearing a Rearrangement of the MLL Gene | completed | Phase 1 | 18 | Epizyme, Inc.INDUSTRY | 2 | Jun 18, 2023 | clinicaltrials |
| NCT02299518 | Selinexor and Chemotherapy in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia | completed | Phase 1 | 23 | Alice MimsOTHER | 1 | Jun 15, 2023 | clinicaltrials |
| NCT05188326 | Efficacy of 5-Aza for Post-Remission Therapy of Acute Myeloid Leukemia (AML) in Elderly Patients | completed | Phase 3 | 54 | Associazione Qol-oneOTHER | 1 | Jun 8, 2023 | clinicaltrials |
| NCT04484532 | Evaluation of Antibody Response to High-Dose Seasonal Influenza Vaccination in Patients With Myeloid Malignancy Receiving Chemotherapy and Healthy Volunteers | completed | Early Phase 1 | 130 | Roswell Park Cancer InstituteOTHER | 1 | Jun 6, 2023 | clinicaltrials |
Data updated 23 days agoSource updated Nov 7, 2023source: clinicaltrials